0001567892-20-000004.txt : 20200225 0001567892-20-000004.hdr.sgml : 20200225 20200225061938 ACCESSION NUMBER: 0001567892-20-000004 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20200225 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200225 DATE AS OF CHANGE: 20200225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Mallinckrodt plc CENTRAL INDEX KEY: 0001567892 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981088325 FISCAL YEAR END: 1227 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35803 FILM NUMBER: 20647183 BUSINESS ADDRESS: STREET 1: 3 LOTUS PARK, THE CAUSEWAY STREET 2: STAINES-UPON-THAMES CITY: SURREY STATE: X0 ZIP: TW18 3AG BUSINESS PHONE: 44-017-8463-6700 MAIL ADDRESS: STREET 1: 3 LOTUS PARK, THE CAUSEWAY STREET 2: STAINES-UPON-THAMES CITY: SURREY STATE: X0 ZIP: TW18 3AG 8-K 1 mnk8-k022520.htm 8-K Document
false0001567892 0001567892 2020-02-25 2020-02-25



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): February 25, 2020
 
Mallinckrodt plc

(Exact name of registrant as specified in its charter)
Ireland
001-35803
98-1088325
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
3 Lotus Park, The Causeway, Staines-Upon-Thames
Surrey TW18 3AG, United Kingdom
(Address of principal executive offices) (Zip Code)
 
Registrant's telephone number, including area code:  +44 017 8463 6700
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
(Title of each class)
(Trading Symbol(s))
(Name of each exchange on which registered)
Ordinary shares, par value $0.20 per share
MNK
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐






Item 2.02    Results of Operations and Financial Condition.

On February 25, 2020, Mallinckrodt plc issued a press release announcing financial results for the quarter and year ended December 27, 2019. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in Items 2.02 and 9.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as otherwise expressly set forth by specific reference in such a filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits
Exhibit No.
 
Exhibit
99.1
 
104
 
Cover Page Interactive Data File (embedded within the inline XBRL document).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 







SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
 
 
MALLINCKRODT PLC
 
 
 
 
(registrant)
 
 
 
 
 
Date:
February 25, 2020
 
By:
/s/ Bryan M. Reasons
 
 
 
 
Bryan M. Reasons
 
 
 
 
Executive Vice President and Chief Financial Officer
(principal financial officer)




 EX-99.1 2 mnkexhibit991q42019er.htm EXHIBIT 99.1 Exhibit


Exhibit 99.1

mallinckrodtlogoa11.jpg

Mallinckrodt plc Reports Strong Fourth Quarter and 2019 Results

•
Fourth quarter net sales of $804.9 million and 2019 net sales of $3.163 billion, with strong performance across hospital products and the Specialty Generics segment, offset by declines in Acthar® Gel

•
Diluted loss per share of $13.76 in the fourth quarter and $11.88 in fiscal 2019; adjusted diluted earnings per share (EPS) of $2.40 in the fourth quarter and $8.88 in fiscal 2019

•
Fourth quarter operating cash flow of $208.8 million and free cash flow of $184.5 million; fiscal 2019 operating cash flow of $742.9 million and free cash flow of $609.9 million

•
Principal debt reduced by $733.9 million in fiscal 2019, with net debt reduced by $1.176 billion, reflecting strong cash-generation, debt repurchased at a discount and the debt exchange offer completed in the fourth quarter

•
As separately announced today, reached an agreement in principle for a global settlement with a broad-based group of plaintiffs that would resolve all opioid-related claims against the company and its subsidiaries, and taking actions to address near-term maturities to strengthen capital structure

STAINES-UPON-THAMES, United Kingdom - Feb. 25, 2020 - Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today reported results for the three months and fiscal year ended Dec. 27, 2019. Unless otherwise noted, the three months and fiscal year comparisons are to the prior year comparable period ended Dec. 28, 2018.

Net sales were $804.9 million in the quarter with diluted loss per share of $13.76, primarily driven by $1.643 billion in expense associated with the agreement in principle pertaining to a global opioid resolution, partially offset by a $377.4 million gain on debt extinguishment. Adjusted diluted EPS was $2.40 versus $2.18, an increase of 10.1%.

”We are pleased with the operating strength of the business as we finished 2019,” said Mark Trudeau, President and Chief Executive Officer of Mallinckrodt. "Our hospital products had an exceptional fourth quarter, as we anticipated, and the Specialty Generics segment finished the year strong, marking its fourth consecutive quarter of growth. Acthar® Gel performed largely in line with our expectations given a challenging payer environment. We remain focused on executing our long-term strategy for this product by generating clinically meaningful data and exploring opportunities to drive greater access for patients. At the same time, we continue to advance our pipeline, including preparing for approval submissions for terlipressin and StrataGraft® in the coming months.”

Trudeau continued, "Over the past year, it has been one of our top priorities to remove three uncertainties impacting our business - opioid litigation, near-term debt maturities and the Acthar CMS1 matter. We are pleased that we now have what we believe to be a clear path forward for resolving two of those: reaching an agreement in principle on the terms of a comprehensive global opioid resolution, and taking steps to






strengthen our capital structure by addressing near term maturities. While managing these uncertainties, we remain focused on achieving our long-term vision of becoming an innovation-driven biopharmaceutical company focused on improving outcomes for underserved patients with severe and critical conditions."

COMPANY FINANCIAL RESULTS

Fourth Quarter 2019 Results
Gross profit was $373.1 million with gross profit as a percentage of net sales of 46.4%, compared with 43.5%, driven by inventory step-up expense in the prior period and product mix. Adjusted gross profit was $575.9 million, compared with $608.0 million, with adjusted gross profit as a percentage of net sales of 71.5%, compared with 72.8%, driven primarily by product mix.

Selling, general and administrative (SG&A) expenses were $169.2 million or 21.0% of net sales, as compared to $239.6 million, or 28.7%, driven primarily by legal settlement expenses in the prior period and the change in the fair value of contingent consideration. Adjusted SG&A expenses were $191.6 million or 23.8% of net sales, compared with $212.2 million or 25.4%. Adjusted SG&A expenses decreased due to ongoing focused efforts on SG&A reductions.

Research and development expenses were $81.4 million or 10.1% of net sales, as compared to $100.4 million or 12.0%, due to the completion of certain development programs.

As a result of the agreement in principle for a global opioid resolution, the company recorded a $1.643 billion expense attributed to the anticipated structured cash payments under the settlement agreement and the anticipated warrants to purchase ordinary shares at $3.15 per share representing approximately 19.99% of the company’s fully diluted outstanding shares, including after giving effect to the exercise of the warrants.

The company recorded $274.5 million in non-recurring impairments in the quarter, related to its VTS-270 in-process research and development intangible asset; as compared to $3.891 billion in the prior year, which was primarily attributed to the goodwill impairment.

Interest expense was $77.2 million as compared to $90.1 million, a reduction of 14.3%, driven by our continued focus on deleveraging.

Income tax benefit was $327.7 million, for an effective tax rate of 22.0%. The adjusted effective tax rate was 15.5%.

Fiscal Year 2019 Results
Net sales were $3.163 billion, compared with $3.216 billion. The decrease was primarily attributed to Acthar® Gel (repository corticotropin injection), partially offset by strength in the hospital products, AMITIZA® (lubiprostone) and the Specialty Generics segment.

On a GAAP2 basis, net loss was $996.5 million, compared with $3.607 billion, with diluted loss per share of $11.88 compared to $42.94, both periods impacted by significant one-time items with the opioid agreement in principle liability in 2019 and the goodwill impairment in 2018.

Adjusted net income was $747.5 million, compared with $682.2 million. Adjusted diluted EPS was $8.88 compared with $8.01, an increase of 10.9%.



BUSINESS SEGMENT RESULTS

Specialty Brands Segment
Net sales for the segment in the fourth quarter 2019 were $611.4 million.

•
Acthar® Gel net sales were $232.6 million, a 17.8% decrease, primarily driven by continued reimbursement challenges impacting new and returning patients and continued payer scrutiny on overall specialty pharmaceutical spending.

•
INOMAX® (nitric oxide) gas, for inhalation net sales were $143.8 million, an increase of 3.7%, or 3.8% on a constant-currency basis, driven by strong customer demand for INOmax, partially offset by increased competition in the market.

•
OFIRMEV® (acetaminophen) injection net sales were $111.8 million, an increase of 28.2%, primarily due to significant quarter-to-quarter order variability that is expected to continue until loss of exclusivity.

•
Therakos® immunology platform net sales were $63.3 million, an increase of 11.1%, or 11.3% on a constant-currency basis, primarily due to the capture of new patients, and the conversion to the Cellex device.

•
AMITIZA net sales were $50.9 million, down 21.2% due to lower royalties in the U.S. due to an increasingly competitive landscape.

Specialty Generics Segment
The segment reported fourth quarter net sales in 2019 of $193.5 million, an increase of 6.0%.

LIQUIDITY
Cash provided by operating activities in the fourth quarter was $208.8 million, with free cash flow of $184.5 million. For the year, operating cash flow was $742.9 million and free cash flow $609.9 million.

The cash balance at the end of the year was $790.9 million, and the revolving credit facility was fully drawn. During the fourth quarter, the company executed a debt exchange offer, which reduced total debt by $383.2 million. With this exchange offer, cash generated from operations, and debt repurchased at a discount earlier in the year, the company reduced net debt by $1.176 billion in 2019, and ended the year with net debt of $4.632 billion.

In conjunction with announcing the agreement in principle for a global opioid resolution, the company also announced that it has entered into certain agreements relating to potential financing and debt exchange transactions, which if implemented, will address near-term debt maturities of the company.

CONFERENCE CALL AND WEBCAST
Mallinckrodt will hold a conference call today at 8:30 a.m. U.S. Eastern Time. This call can be accessed in three ways:
•
At the Mallinckrodt website: http://www.mallinckrodt.com/investors.
•
By telephone: For both listen-only participants and those who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is (877) 359-9508. For participants outside the U.S., the dial-in number is (224) 357-2393. Callers will need to provide the Conference ID of 4168459.
•
Through an audio replay: A replay of the call will be available beginning at 11:30 a.m. Eastern Time on Tuesday, Feb. 25, 2020, and ending at 11:30 a.m. Eastern Time on Tuesday, March 10,


2020. Dial-in numbers for U.S.-based participants are (855) 859-2056 or (800) 585-8367. Participants outside the U.S. should use the replay dial-in number of (404) 537-3406. All callers will be required to provide the Conference ID of 4168459.

ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

NON-GAAP FINANCIAL MEASURES
This press release contains financial measures, including adjusted net income, adjusted diluted earnings per share, adjusted gross profit, adjusted SG&A, net sales growth on a constant-currency basis, adjusted effective tax rate, net debt and free cash flow, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations.
    
Adjusted net income, adjusted gross profit and adjusted SG&A represent amounts prepared in accordance with accounting principles generally accepted in the U.S. (GAAP) and adjusted for certain items that management believes are not reflective of the operational performance of the business. The adjustments for these items are on a pre-tax basis for adjusted gross profit and adjusted SG&A and on an after-tax basis for adjusted net income. Adjustments to GAAP amounts include, as applicable to each measure, amortization and non-restructuring impairment charges; restructuring and related charges, net; inventory step-up expenses; discontinued operations; changes in fair value of contingent consideration obligations; acquisition-related expenses; significant legal and environmental charges; losses on divestiture; unrealized gain on equity investment; gains on debt extinguishment, net; separation costs; research and development upfront payments; tax effects of aforementioned adjustments, changes in related uncertain tax positions, as well as impacts from certain transactions, such as acquisitions or reorganizations; and other items identified by the company. Adjusted diluted earnings per share represent adjusted net income divided by the number of diluted shares.

The adjusted effective tax rate is calculated as the income tax effects on continuing and discontinued operations plus the income tax impact included in Mallinckrodt’s reconciliation of net loss, divided by loss from continuing and income from discontinued operations plus the pre-tax, non-income, tax-related adjustments included in its reconciliation of adjusted net income (excluding dilutive share impact). The income tax adjustment included in the reconciliation of adjusted net income primarily represents the tax impact of adjustments between net loss and adjusted net income, changes in related uncertain tax positions, as well as tax impacts from certain transactions, such as acquisitions or reorganizations.



Net sales growth on a constant-currency basis measures the change in net sales between current- and prior-year periods using a constant currency, the exchange rate in effect during the applicable prior-year period.

Free cash flow for the fourth quarter represents net cash provided by operating activities of $208.8 million less capital expenditures of $24.3 million, each as prepared in accordance with GAAP.

Free cash flow for the fiscal year represents net cash provided by operating activities of $742.9 million less capital expenditures of $133.0 million, each as prepared in accordance with GAAP.

Net debt as of Dec. 27, 2019 represents the total principal debt outstanding of $5.423 billion less unrestricted cash of $790.9 million, each as prepared in accordance with GAAP.

Net debt as of Dec. 28, 2018 represents the total principal debt outstanding of $6.157 billion less unrestricted cash of $348.9 million, each as prepared in accordance with GAAP.

The company has provided these adjusted financial measures because they are used by management, along with financial measures in accordance with GAAP, to evaluate the company's operating performance. In addition, the company believes that they will be used by certain investors to measure Mallinckrodt's operating results. Management believes that presenting these adjusted measures provides useful information about the company's performance across reporting periods on a consistent basis by excluding items that the company does not believe are indicative of its core operating performance.

These adjusted measures should be considered supplemental to and not a substitute for financial information prepared in accordance with GAAP. The company's definition of these adjusted measures may differ from similarly titled measures used by others.

Because adjusted financial measures exclude the effect of items that will increase or decrease the company's reported results of operations, management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of certain of these historical adjusted financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.

Further information regarding non-GAAP financial measures can be found on the Investor Relations page of the company’s website.

CAUTIONARY STATEMENTS RELATED TO FORWARD-LOOKING STATEMENTS
Statements in this document that are not strictly historical, including statements regarding future financial condition and operating results, legal, economic, business, competitive and/or regulatory factors affecting Mallinckrodt's businesses, and any other statements regarding events or developments the company believes or anticipates will or may occur in the future, may be "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties.

There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include risks and uncertainties related to, among other things: governmental investigations and inquiries, regulatory actions and lawsuits brought against Mallinckrodt by government agencies and private parties with respect to its historical commercialization of opioids, including the non-binding agreement in principle regarding terms and conditions of a global settlement to resolve all current and future opioid-related claims; scrutiny from governments, legislative


bodies and enforcement agencies related to sales, marketing and pricing practices; pricing pressure on certain of Mallinckrodt’s products due to legal changes or changes in insurers’ reimbursement practices resulting from recent increased public scrutiny of healthcare and pharmaceutical costs; the reimbursement practices of governmental health administration authorities, private health coverage insurers and other third-party payers; complex reporting and payment obligations under the Medicare and Medicaid rebate programs and other governmental purchasing and rebate programs; cost containment efforts of customers, purchasing groups, third-party payers and governmental organizations; changes in or failure to comply with relevant laws and regulations; Mallinckrodt's and its partners’ ability to successfully develop or commercialize new products or expand commercial opportunities; Mallinckrodt's ability to navigate price fluctuations; competition; Mallinckrodt's and its partners’ ability to protect intellectual property rights; limited clinical trial data for Acthar Gel; clinical studies and related regulatory processes; product liability losses and other litigation liability; material health, safety and environmental liabilities; potential indemnification liabilities to Covidien pursuant to the separation and distribution agreement; business development activities; retention of key personnel; the effectiveness of information technology infrastructure including cybersecurity and data leakage risks; customer concentration; Mallinckrodt's reliance on certain individual products that are material to its financial performance; Mallinckrodt's ability to receive procurement and production quotas granted by the U.S. Drug Enforcement Administration; complex manufacturing processes; conducting business internationally; Mallinckrodt's ability to achieve expected benefits from restructuring activities; Mallinckrodt’s significant levels of intangible assets and related impairment testing; labor and employment laws and regulations; natural disasters or other catastrophic events; Mallinckrodt’s substantial indebtedness and its ability to generate sufficient cash to reduce its indebtedness; the proposed refinancing of certain near-term debt maturities; future changes to U.S. and foreign tax laws or the impact of disputes with governmental tax authorities; and the impact of Irish laws.

These and other factors are identified and described in more detail in the "Risk Factors" section of Mallinckrodt's Annual Report on Form 10-K for the fiscal year ended December 27, 2019, which the company expects to file later today. The forward-looking statements made herein speak only as of the date hereof and Mallinckrodt does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.

CONTACTS

Investor Relations    
Daniel J. Speciale, CPA
Vice President, Investor Relations and IRO
314-654-3638
daniel.speciale@mnk.com

Media
Michael Freitag / Aaron Palash / Aura Reinhard
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

1 Centers for Medicare & Medicaid Services
2 Generally accepted accounting principles in the United States

Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2020 Mallinckrodt. 02/20


MALLINCKRODT PLC
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in millions, except per share data)
 
 
 
 
 
 
 
Three Months Ended
 
December 27,
2019
Percent of
Net sales
 
December 28,
2018
Percent of
Net sales
Net sales
$
804.9

100.0
 %
 
$
834.9

100.0
 %
Cost of sales
431.8

53.6

 
471.6

56.5

Gross profit
373.1

46.4

 
363.3

43.5

Selling, general and administrative expenses
169.2

21.0

 
239.6

28.7

Research and development expenses
81.4

10.1

 
100.4

12.0

Restructuring charges, net
(12.9
)
(1.6
)
 
1.2

0.1

Non-restructuring impairment charges
274.5

34.1

 
3,891.1

466.1

Losses on divestiture
33.5

4.2

 
0.2

—

Opioid-related litigation settlement charge
1,643.4

204.2

 
—

—

Operating loss
(1,816.0
)
(225.6
)
 
(3,869.2
)
(463.4
)
Interest expense
(77.2
)
(9.6
)
 
(90.1
)
(10.8
)
Interest income
2.9

0.4

 
1.6

0.2

Gain on debt extinguishment, net
377.4

46.9

 
5.7

0.7

Other income, net
24.2

3.0

 
7.4

0.9

Loss from continuing operations before income taxes
(1,488.7
)
(185.0
)
 
(3,944.6
)
(472.5
)
Income tax benefit
(327.7
)
(40.7
)
 
(226.2
)
(27.1
)
Loss from continuing operations
(1,161.0
)
(144.2
)
 
(3,718.4
)
(445.4
)
Income from discontinued operations, net of income taxes
3.9

0.5

 
—

—

Net loss
$
(1,157.1
)
(143.8
)%
 
$
(3,718.4
)
(445.4
)%
 

 
 
 
 
Basic (loss) earnings per share:

 
 
 
 
Loss from continuing operations
$
(13.80
)
 
 
$
(44.64
)
 
Income from discontinued operations
0.05

 
 
—

 
Net loss
(13.76
)
 
 
(44.64
)
 
Diluted (loss) earnings per share:

 
 
 
 
Loss from continuing operations
$
(13.80
)
 
 
$
(44.64
)
 
Income from discontinued operations
0.05

 
 
—

 
Net loss
(13.76
)
 
 
(44.64
)
 
Weighted-average number of shares outstanding:

 
 
 
 
Basic
84.1

 
 
83.3

 
Diluted
84.1

 
 
83.3

 
 
 
 
 
 
 





MALLINCKRODT PLC
NON-GAAP MEASURES
(unaudited, in millions except per share data)
 
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended
 
December 27, 2019
 
December 28, 2018
 
Gross profit
SG&A
Net (loss) income
 
Diluted
net (loss) income
per share(1)
 
Gross profit
SG&A
Net (loss) income
 
Diluted net (loss) income per share(1)
GAAP
$
373.1

$
169.2

$
(1,157.1
)

$
(13.76
)
 
$
363.3

$
239.6

$
(3,718.4
)
 
$
(44.64
)
Adjustments:





 
 
 
 
 
 
Intangible asset amortization
202.8

(0.8
)
203.6


2.42

 
192.0

(1.7
)
193.7

 
2.28

Restructuring and related charges, net (2)
—

—

(12.9
)

(0.15
)
 
—

(0.3
)
1.5

 
0.02

Inventory step-up expense
—

—

—


—

 
41.3

—

41.3

 
0.49

Income from discontinued operations
—

—

(3.9
)

(0.05
)
 
—

—

—

 
—

Change in contingent consideration fair value
—

36.7

(36.7
)

(0.44
)
 
—

16.9

(16.9
)
 
(0.20
)
Acquisition related expenses
—

—

—


—

 
—

(2.0
)
2.0

 
0.02

Non-restructuring impairment charges (3)
—

—

274.5


3.26

 
—

—

3,891.1

 
45.83

Significant legal and environmental charges (4)
—

—

1,643.4


19.52

 
—

(31.5
)
31.5

 
0.37

Divestitures
—

—

33.5


0.40

 
—

—

0.2

 
—

Separation costs
—

(13.5
)
13.5


0.16

 
—

(6.0
)
6.0

 
0.07

Gains on debt extinguishment, net
—

—

(377.4
)

(4.48
)
 
—

—

(6.2
)
 
(0.07
)
Unrealized gain on equity investment (5)
—

—

(13.7
)
 
(0.16
)
 
—

—

—

 
—

Legal entity and intercompany financing organization
—

—

(26.0
)

(0.31
)
 
—

—

(173.7
)
 
(2.05
)
U.S. Tax Reform
—

—

—


—

 
—

—

0.6

 
0.01

Income taxes (6)
—

—

(338.7
)

(4.02
)
 
—

—

(81.6
)
 
(0.96
)
Depreciation catch up (7)
—

—

—


—

 
11.4

(2.8
)
13.7

 
0.16

As adjusted
$
575.9

$
191.6

$
202.1


$
2.40

 
$
608.0

$
212.2

$
184.8

 
$
2.18

 





 
 
 
 
 
 
Percent of net sales
71.5
%
23.8
%
25.1
%


 
72.8
%
25.4
%
22.1
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) 
In periods where losses from continuing operations are incurred, potential ordinary shares outstanding are excluded from the calculation of diluted earnings per share, prepared in accordance with GAAP, as they would be anti-dilutive. These dilutive shares are included in the calculation of adjusted diluted earnings per share if dilutive to adjusted net income. As a result, the adjusted diluted earnings per share utilized a weighted average share count of 84.2 and 84.9 shares for the three months ended December 27, 2019 and December 28, 2018, respectively.
(2) 
Includes pre-tax accelerated depreciation.
(3) 
The three months ended December 27, 2019 includes an in-process research and development ("IPR&D") intangible asset impairment of $274.5 million related to VTS-270. The three months ended December 28, 2018 includes the goodwill impairment of $3,672.8 million and an IPR&D intangible asset impairment of $218.3 million related to MNK-1411.
(4) 
Includes the opioid-related litigation settlement charge of $1.643 billion.
(5) 
Represents an unrealized gain related to the company's equity investment in Silence Therapeutics plc ("Silence").
(6) 
Includes tax effects of above adjustments (unless otherwise separately stated), changes in related uncertain tax positions, as well as certain installment sale transactions and other intercompany transactions.
(7) 
During the three months ended December 28, 2018, "the Specialty Generics Disposal Group" was reclassified to held and used after being classified as held-for-sale since February 2018.  In accordance with GAAP, depreciation and amortization are not recorded during the period in which a disposal group is classified as held-for-sale.  When the disposal group was reclassified to held and used, it was measured at its carrying amount before it was classified as held-for-sale, adjusted for depreciation and amortization expense that would have been recognized had the disposal group been continuously classified as held and used.  The effect of the required adjustment has been reflected in loss from continuing operations during the fourth quarter of 2018, the period in which the held-for-sale criteria was no longer met.
This adjustment represents $17.7 million of depreciation expense, net of tax of $4.0 million, recorded during the three months ended December 28, 2018 that would have been recognized during the first three quarters of fiscal 2018 had the Specialty Generics Disposal Group been continuously classified as held and used. This will not be reflected in the fiscal 2018 non-GAAP measures table as the catch-up in the three months ended December 28, 2018 results in an accurate depiction of total depreciation expense for fiscal 2018. Consistent with historical periods, intangible asset amortization is a non-GAAP adjustment and is therefore not called out separately as a result in the change in classification of the disposal group.



MALLINCKRODT PLC
SEGMENT NET SALES AND CONSTANT-CURRENCY GROWTH
(unaudited, in millions)
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended
 
 
 
 
 
 
 
December 27,
2019
 
December 28,
2018
 
Percent
change
 
Currency impact
 
Constant-currency growth
Specialty Brands
$
611.4

 
$
652.4

 
(6.3
)%
 
—
%
 
(6.3
)%
Specialty Generics(1)
193.5

 
182.5

 
6.0

 
—

 
6.0

Net sales
$
804.9

 
$
834.9

 
(3.6
)
 
—

 
(3.6
)
 
 
 
 
 
 
 
 
 
 
(1) 
Includes net sales from the post-divestiture supply agreement with the acquirer of the contrast media and delivery systems ("CMDS") business.

MALLINCKRODT PLC
SELECT PRODUCT LINE NET SALES
(unaudited, in millions)
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended
 
 
 
 
 
 
 
December 27,
2019
 
December 28,
2018
 
Percent
change
 
Currency impact
 
Constant-currency growth
Specialty Brands
 
 
 
 
 
 
 
 
 
Acthar Gel
$
232.6

 
$
283.0

 
(17.8
)%
 
—
 %
 
(17.8
)%
INOmax
143.8

 
138.7

 
3.7

 
(0.1
)
 
3.8

Ofirmev
111.8

 
87.2

 
28.2

 
—

 
28.2

Therakos
63.3

 
57.0

 
11.1

 
(0.2
)
 
11.3

Amitiza
50.9

 
64.6

 
(21.2
)
 
—

 
(21.2
)
BioVectra (1)
3.3

 
17.4

 
(81.0
)
 
(0.2
)
 
(80.8
)
Other
5.7

 
4.5

 
26.7

 
(0.4
)
 
27.1

Specialty Brands Total
$
611.4

 
$
652.4

 
(6.3
)%
 
—
 %
 
(6.3
)%
 
 
 
 
 
 
 
 
 
 
Specialty Generics
 
 
 
 
 
 
 
 
 
Hydrocodone (API) and hydrocodone-containing tablets
$
25.1

 
$
19.6

 
28.1
 %
 
—
 %
 
28.1
 %
Oxycodone (API) and oxycodone-containing tablets (2)
21.6

 
22.8

 
(5.3
)
 
—

 
(5.3
)
Acetaminophen (API) (2)
46.8

 
43.7

 
7.1

 
—

 
7.1

Other controlled substances (2)
86.8

 
85.8

 
1.2

 
—

 
1.2

Other (2)
13.2

 
10.6

 
24.5

 
—

 
24.5

Specialty Generics Total
$
193.5

 
$
182.5

 
6.0
 %
 
—
 %
 
6.0
 %
(1) 
In November 2019, the company completed its sale of the BioVectra business.
(2) 
Prior period amounts have been reclassified to conform to current period presentation.



MALLINCKRODT PLC
SEGMENT OPERATING INCOME
(unaudited, in millions)
 
 
 
 
 
Three Months Ended
 
December 27,
2019
 
December 28,
2018
Specialty Brands (1)
$
310.3

 
$
298.7

Specialty Generics (2)
28.0

 
(5.4
)
Segment operating income
338.3

 
293.3

Unallocated amounts:
 
 
 
Corporate and allocated expenses (3)          
(32.2
)
 
(70.1
)
Intangible asset amortization
(203.6
)
 
(193.7
)
Restructuring and related charges, net (4)
12.9

 
(1.6
)
Non-restructuring impairments
(274.5
)
 
(3,891.1
)
Separation costs
(13.5
)
 
(6.0
)
Opioid-related litigation settlement charge
(1,643.4
)
 
—

Operating loss
$
(1,816.0
)
 
$
(3,869.2
)
(1) 
The three months ended December 28, 2018 includes $41.3 million of inventory fair-value step up expense related to Amitiza.
(2) 
During the fourth quarter of 2018, the Specialty Generics Disposal Group was reclassified to held-and-used and measured at its carrying amount before it was classified as held-for-sale, adjusted for depreciation and amortization expense that would have been recognized had the disposal group been continuously classified as held and used. The total depreciation adjustment of $17.7 million was reflected in the Specialty Generics segment operating income during the fourth quarter of 2018, the period in which the held-for-sale criteria were no longer met.
(3) 
Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the company's reportable segments.
(4) 
Includes restructuring-related accelerated depreciation.



MALLINCKRODT PLC
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in millions, except per share data)
 
 
 
 
 
 
 
Fiscal Year
 
2019
Percent of
Net sales
 
2018
Percent of
Net sales
Net sales
$
3,162.5

100.0
 %
 
$
3,215.6

100.0
 %
Cost of sales
1,741.1

55.1

 
1,744.4

54.2

Gross profit
1,421.4

44.9

 
1,471.2

45.8

Selling, general and administrative expenses
831.0

26.3

 
834.1

25.9

Research and development expenses
349.4

11.0

 
361.1

11.2

Restructuring charges, net
(1.7
)
(0.1
)
 
103.0

3.2

Non-restructuring impairment charges
388.0

12.3

 
3,893.1

121.1

Losses on divestiture
33.5

1.1

 
0.8

—

Opioid-related litigation settlement charge
1,643.4

52.0

 
—

—

Operating loss
(1,822.2
)
(57.6
)
 
(3,720.9
)
(115.7
)
Interest expense
(309.0
)
(9.8
)
 
(370.2
)
(11.5
)
Interest income
9.5

0.3

 
8.2

0.3

Gain on debt extinguishment, net
466.6

14.8

 
8.5

0.3

Other income, net
63.6

2.0

 
22.4

0.7

Loss from continuing operations before income taxes
(1,591.5
)
(50.3
)
 
(4,052.0
)
(126.0
)
Income tax benefit
(584.3
)
(18.5
)
 
(430.1
)
(13.4
)
Loss from continuing operations
(1,007.2
)
(31.8
)
 
(3,621.9
)
(112.6
)
Income from discontinued operations, net of income taxes
10.7

0.3

 
14.9

0.5

Net loss
$
(996.5
)
(31.5
)%
 
$
(3,607.0
)
(112.2
)%
 
 
 
 
 
 
Basic (loss) earnings per share:
 
 
 
 
 
Loss from continuing operations
$
(12.00
)
 
 
$
(43.12
)
 
Income from discontinued operations
0.13

 
 
0.18

 
Net loss
(11.88
)
 
 
(42.94
)
 
Diluted (loss) earnings per share:
 
 
 
 
 
Loss from continuing operations
$
(12.00
)
 
 
$
(43.12
)
 
Income from discontinued operations
0.13

 
 
0.18

 
Net loss
(11.88
)
 
 
(42.94
)
 
Weighted-average number of shares outstanding:
 
 
 
 
 
Basic
83.9

 
 
84.0

 
Diluted
83.9

 
 
84.0

 
 
 
 
 
 
 





MALLINCKRODT PLC
NON-GAAP MEASURES
(unaudited, in millions except per share data)
 
 
 
 
 
 
 
 
 
 
 
 
 
Fiscal Year
 
2019
 
2018
 
Gross profit
SG&A
Net (loss) income
 
Diluted
net (loss) income
per share(1)
 
Gross profit
SG&A
Net (loss) income
 
Diluted
net (loss) income
per share(1)
GAAP
$
1,421.4

$
831.0

$
(996.5
)
 
$
(11.88
)
 
$
1,471.2

$
834.1

$
(3,607.0
)
 
$
(42.94
)
Adjustments:
 
 
 
 
 
 
 
 
 
 
 
Intangible asset amortization
847.9

(5.5
)
853.4

 
10.14

 
733.6

(6.6
)
740.2

 
8.69

Restructuring and related charges, net (2)
—

—

(1.7
)
 
(0.02
)
 
3.0

(2.2
)
108.2

 
1.27

Inventory step-up expense
10.0

—

10.0

 
0.12

 
120.8

—

120.8

 
1.42

Income from discontinued operations
—

—

(10.7
)
 
(0.13
)
 
—

—

(14.9
)
 
(0.17
)
Change in contingent consideration fair value
—

60.2

(60.2
)
 
(0.71
)
 
—

50.2

(50.2
)
 
(0.59
)
Acquisition related expenses
—

—

—

 
—

 
—

(5.8
)
5.8

 
0.07

Non-restructuring impairment charges (3)
—

—

388.0

 
4.61

 
—

—

3,893.1

 
45.69

Significant legal and environmental charges (4)
—

(28.2
)
1,671.6

 
19.85

 
—

(19.7
)
19.7

 
0.23

Divestitures
—

—

33.5

 
0.40

 
—

—

0.8

 
0.01

R&D upfront payment
—

—

20.0

 
0.24

 
—

—

—

 
—

Separation costs
—

(63.9
)
63.9

 
0.76

 
—

(6.0
)
6.0

 
0.07

Gains on debt extinguishment, net
—

—

(466.6
)
 
(5.54
)
 
—

—

(12.7
)
 
(0.15
)
Unrealized gain on equity investment (5)
—

—

(20.2
)
 
(0.24
)
 
—

—

—

 
—

Legal entity and intercompany financing organization
—

—

(212.8
)
 
(2.53
)
 
—

—

(256.0
)
 
(3.00
)
U.S. Tax Reform
—

—

—

 
—

 
—

—

(8.5
)
 
(0.10
)
Income taxes (6)
—

—

(524.2
)
 
(6.23
)
 
—

—

(263.1
)
 
(3.09
)
As adjusted
$
2,279.3

$
793.6

$
747.5

 
$
8.88

 
$
2,328.6

$
844.0

$
682.2

 
$
8.01

 
 
 
 
 
 
 
 
 
 
 
 
Percent of net sales
72.1
%
25.1
%
23.6
%
 
 
 
72.4
%
26.2
%
21.2
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) 
In periods where losses from continuing operations are incurred, potential ordinary shares outstanding are excluded from the calculation of diluted earnings per share, prepared in accordance with GAAP, as they would be anti-dilutive. These dilutive shares are included in the calculation of adjusted diluted earnings per share if dilutive to adjusted net income. As a result, the adjusted diluted earnings per share utilized a weighted average share count of 84.2 and 85.2 shares for fiscal 2019 and 2018, respectively.
(2) 
Includes pre-tax accelerated depreciation.
(3) 
Fiscal 2019 includes IPR&D intangible asset impairments of $274.5 and $113.5 million related to VTS-270 and stannsoporfin, respectively. Fiscal 2018 includes the goodwill impairment of $3,672.8 million and an IPR&D intangible asset impairment of $218.3 million related to MNK-1411.
(4) 
Includes the opioid-related litigation settlement charge of $1.643 billion.
(5) 
Represents an unrealized gain related to the company's equity investment in Silence. Fiscal 2019 includes an unrealized gain of $6.5 million and $13.7 million for the three months ended September 27, 2019 and the three months ended December 27, 2019, respectively.
(6) 
Includes tax effects of above adjustments (unless otherwise separately stated), changes in related uncertain tax positions, as well as certain installment sale transactions and other intercompany transactions.



MALLINCKRODT PLC
SEGMENT NET SALES AND CONSTANT-CURRENCY GROWTH
(unaudited, in millions)
 
 
 
 
 
 
 
 
 
 
 
Fiscal Year
 
 
 
 
 
 
 
2019
 
2018
 
Percent
change
 
Currency impact
 
Constant-currency growth
Specialty Brands
$
2,423.8

 
$
2,496.7

 
(2.9
)%
 
(0.2
)%
 
(2.7
)%
Specialty Generics(1)
738.7

 
718.9

 
2.8

 
(0.1
)
 
2.9

Net sales
$
3,162.5

 
$
3,215.6

 
(1.7
)
 
(0.2
)
 
(1.5
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) 
Includes net sales from the post-divestiture supply agreement with the acquirer of the CMDS business.

MALLINCKRODT PLC
SELECT PRODUCT LINE NET SALES
(unaudited, in millions)
 
 
 
 
 
 
 
 
 
 
 
Fiscal Year
 
 
 
 
 
 
 
2019
 
2018
 
Percent
change
 
Currency impact
 
Constant-currency growth
Specialty Brands
 
 
 
 
 
 
 
 
 
Acthar Gel
$
952.7

 
$
1,110.1

 
(14.2
)%
 
—
 %
 
(14.2
)%
INOmax
571.4

 
542.7

 
5.3

 
(0.1
)
 
5.4

Ofirmev
384.0

 
341.9

 
12.3

 
—

 
12.3

Therakos
246.9

 
231.2

 
6.8

 
(1.5
)
 
8.3

Amitiza
208.5

 
183.8

 
13.4

 
—

 
13.4

BioVectra (1)
40.1

 
53.1

 
(24.5
)
 
(2.3
)
 
(22.2
)
Other
20.2

 
33.9

 
(40.4
)
 
(1.0
)
 
(39.4
)
Specialty Brands Total
$
2,423.8

 
$
2,496.7

 
(2.9
)%
 
(0.2
)%
 
(2.7
)%
 
 
 
 
 
 
 
 
 

Specialty Generics
 
 
 
 
 
 
 
 

Hydrocodone (API) and hydrocodone-containing tablets
$
76.3

 
$
65.9

 
15.8
 %
 
—
 %
 
15.8
 %
Oxycodone (API) and oxycodone-containing tablets (2)
74.9

 
66.1

 
13.3

 
—

 
13.3

Acetaminophen (API) (2)
189.9

 
192.7

 
(1.5
)
 
—

 
(1.5
)
Other controlled substances (2)
352.5

 
343.8

 
2.5

 
(0.1
)
 
2.6

Other (2)
45.1

 
50.4

 
(10.5
)
 
—

 
(10.5
)
Specialty Generics Total
$
738.7

 
$
718.9

 
2.8
 %
 
(0.1
)%
 
2.9
 %
(1) 
In November 2019, the company completed its sale of the BioVectra business.
(2) 
Prior period amounts have been reclassified to conform to current period presentation.




MALLINCKRODT PLC
SEGMENT OPERATING INCOME
(unaudited, in millions)
 
 
 
 
 
Fiscal Year
 
2019
 
2018
Specialty Brands (1)
$
1,174.5

 
$
1,093.1

Specialty Generics
108.1

 
89.3

Segment operating income
1,282.6

 
1,182.4

Unallocated amounts:
 
 
 
Corporate and allocated expenses (2)          
(137.8
)
 
(155.8
)
Intangible asset amortization
(853.4
)
 
(740.2
)
Restructuring and related charges, net (3)
1.7

 
(108.2
)
Non-restructuring impairment charges
(388.0
)
 
(3,893.1
)
Separation costs
(63.9
)
 
(6.0
)
R&D upfront payment (4)
(20.0
)
 
—

Opioid-related litigation settlement charge
(1,643.4
)
 
—

Operating loss
$
(1,822.2
)
 
$
(3,720.9
)

(1) 
Includes $10.0 million and $118.8 million of inventory fair-value step up expense, primarily related to Amitiza during fiscal 2019 and 2018, respectively.
(2) 
Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the company's reportable segments.
(3) 
Includes restructuring-related accelerated depreciation.
(4) 
Represents R&D expense incurred related to an upfront payment made to Silence in connection with the license and collaboration agreement entered into in July 2019.


MALLINCKRODT PLC
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in millions)
 
 
 
 
 
December 27,
2019
 
December 28,
2018
Assets
 
 
 
Current Assets:
 
 
 
Cash and cash equivalents
$
790.9

 
$
348.9

Accounts receivable, net
577.5

 
623.3

Inventories
312.1

 
322.3

Prepaid expenses and other current assets
150.2

 
132.7

Total current assets
1,830.7

 
1,427.2

Property, plant and equipment, net
896.5

 
982.0

Intangible assets, net
7,018.0

 
8,282.8

Other assets
593.7

 
185.3

Total Assets
$
10,338.9

 
$
10,877.3

 
 
 
 
Liabilities and Shareholders' Equity
 
 
 
Current Liabilities:
 
 
 
Current maturities of long-term debt
$
633.6

 
$
22.4

Accounts payable
139.8

 
147.5

Accrued payroll and payroll-related costs
105.2

 
124.0

Accrued interest
62.9

 
77.6

Accrued and other current liabilities
485.4

 
572.2

Total current liabilities
1,426.9

 
943.7

Long-term debt
4,741.2

 
6,069.2

Opioid-related litigation settlement liability
1,643.4

 
—

Pension and postretirement benefits
62.4

 
60.5

Environmental liabilities
60.0

 
59.7

Deferred income taxes
11.0

 
324.3

Other income tax liabilities
227.1

 
228.0

Other liabilities
226.2

 
304.6

Total Liabilities
8,398.2

 
7,990.0

Shareholders' Equity:
 
 
 
Preferred shares
—

 
—

Ordinary shares
18.7

 
18.5

Ordinary shares held in treasury at cost
(1,615.7
)
 
(1,617.4
)
Additional paid-in capital
5,562.5

 
5,528.2

Retained deficit
(2,016.9
)
 
(1,017.7
)
Accumulated other comprehensive loss
(7.9
)
 
(24.3
)
Total Shareholders' Equity
1,940.7

 
2,887.3

Total Liabilities and Shareholders' Equity
$
10,338.9

 
$
10,877.3



MALLINCKRODT PLC
CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS
(unaudited, in millions)
 
 
 
 
 
Fiscal Year
 
2019
 
2018
Cash Flows From Operating Activities:
 
 
 
Net Loss
$
(996.5
)
 
$
(3,607.0
)
Adjustments to reconcile net cash from operating activities:
 
 
 
Depreciation and amortization
951.1

 
852.1

Share-based compensation
33.8

 
34.6

Deferred income taxes
(604.3
)
 
(541.5
)
Non-cash impairment charges
388.0

 
3,893.1

Inventory provisions
18.0

 
37.9

Losses on divestiture
33.5

 
0.8

Gain on debt extinguishment, net
(466.6
)
 
(8.5
)
Other non-cash items
(65.7
)
 
(42.4
)
Changes in assets and liabilities, net of the effects of acquisitions:
 
 
 
Accounts receivable, net
31.6

 
(145.8
)
Inventories
(23.1
)
 
63.1

Accounts payable
6.7

 
24.6

Income taxes
(2.1
)
 
99.0

Opioid-related litigation settlement liability
1,600.0

 
—

Other
(161.5
)
 
5.5

Net cash from operating activities
742.9

 
665.5

Cash Flows From Investing Activities:
 
 
 
Capital expenditures
(133.0
)
 
(127.0
)
Acquisitions, net of cash
—

 
(699.9
)
Proceeds from divestiture, net of cash
95.1

 
313.0

Other
29.6

 
33.6

Net cash from investing activities
(8.3
)
 
(480.3
)
Cash Flows From Financing Activities:
 
 
 
Issuance of external debt
695.0

 
690.3

Repayment of external debt
(945.1
)
 
(1,693.6
)
Debt financing costs
(10.1
)
 
(12.1
)
Proceeds from exercise of share options
0.6

 
1.0

Repurchase of shares
(2.6
)
 
(57.5
)
Other
(17.9
)
 
(23.1
)
Net cash from financing activities
(280.1
)
 
(1,095.0
)
Effect of currency rate changes on cash
0.6

 
(1.8
)
Net change in cash, cash equivalents and restricted cash
455.1

 
(911.6
)
Cash, cash equivalents and restricted cash at beginning of period
367.5

 
1,279.1

Cash, cash equivalents and restricted cash at end of period
$
822.6

 
$
367.5

 
 
 
 
Cash and cash equivalents at end of period
$
790.9

 
$
348.9

Restricted cash included in other long-term assets at end of period
31.7

 
18.6

Cash, cash equivalents and restricted cash at end of period
$
822.6

 
$
367.5





 EX-101.SCH 3 mnk-20200225.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 mnk-20200225_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 mnk-20200225_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 mnk-20200225_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Central Index Key Entity Central Index Key Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Address, Country Entity Address, Country City Area Code City Area Code Local Phone Number Local Phone Number Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag EX-101.PRE 7 mnk-20200225_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 mallinckrodtlogoa11.jpg begin 644 mallinckrodtlogoa11.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Document and Entity Information Document
Feb. 25, 2020
Document and Entity Information [Abstract]  
Entity Central Index Key 0001567892
Title of 12(b) Security Ordinary shares, par value $0.20 per share
Written Communications false
Entity Incorporation, State or Country Code L2
Document Type 8-K
Document Period End Date Feb. 25, 2020
Entity Registrant Name Mallinckrodt plc
Entity File Number 001-35803
Entity Tax Identification Number 98-1088325
Entity Address, Address Line One 3 Lotus Park, The Causeway
Entity Address, City or Town Staines-Upon-Thames
Entity Address, Postal Zip Code TW18 3AG
Entity Address, Country GB
City Area Code 017
Local Phone Number 8463 6700
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Trading Symbol MNK
Security Exchange Name NYSE
Entity Emerging Growth Company false
Amendment Flag false

JSON 10 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mnk8-k022520.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "mnk-20200225_cal.xml" ] }, "definitionLink": { "local": [ "mnk-20200225_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "mnk8-k022520.htm" ] }, "labelLink": { "local": [ "mnk-20200225_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "mnk-20200225_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "mnk-20200225.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mnk", "nsuri": "http://www.mallinckrodt.com/20200225", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mnk8-k022520.htm", "contextRef": "D2020Q1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:Security12bTitle", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document and Entity Information Document", "role": "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument", "shortName": "Document and Entity Information Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mnk8-k022520.htm", "contextRef": "D2020Q1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:Security12bTitle", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "mnk_DocumentandEntityInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document and Entity Information [Abstract]", "label": "Document and Entity Information [Abstract]" } } }, "localname": "DocumentandEntityInformationAbstract", "nsuri": "http://www.mallinckrodt.com/20200225", "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 12 mnk8-k022520_htm.xml IDEA: XBRL DOCUMENT 0001567892 2020-02-25 2020-02-25 false 0001567892 8-K 2020-02-25 Mallinckrodt plc L2 001-35803 98-1088325 3 Lotus Park, The Causeway Staines-Upon-Thames TW18 3AG GB 017 8463 6700 false false false false Ordinary shares, par value $0.20 per share MNK NYSE false XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 95 1 false 0 0 false 0 false false R1.htm 0001000 - Document - Document and Entity Information Document Sheet http://www.mallinckrodt.com/role/DocumentAndEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports mnk8-k022520.htm mnk-20200225.xsd mnk-20200225_cal.xml mnk-20200225_def.xml mnk-20200225_lab.xml mnk-20200225_pre.xml mnkexhibit991q42019er.htm http://xbrl.sec.gov/dei/2019-01-31 true true XML 15 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} EXCEL 16 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end ZIP 17 0001567892-20-000004-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001567892-20-000004-xbrl.zip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end